RD3 and central nervous system cancer: The results showed that in TCGA-GBM (p < 0.001, HR = 0.35) and GSE108474 (p = 0.002, HR = 0.72), patients suffering from glioma with a higher expression of RD3 had a significantly better prognosis than the subgroup with lower expression.